Explore published research on dopamine, including study methods and limitations.
A 1992 review found that despite widespread human use, animals would not self-administer THC and evidence of brain reward pathway stimulation was minimal. The newly discovered cannabinoid receptor was opening new research directions.
A major review found THC caused cell death in the hippocampus, produced persistent cognitive deficits, and activated the same dopamine reward pathways as morphine, alcohol, and nicotine.
Two weeks of daily THC made rats hypersensitive to amphetamine's psychosis-like effects after withdrawal, supporting a biological mechanism for cannabis-associated psychosis risk.
Electrophysiology study showing cannabinoids strongly inhibited excitatory inputs to the brain's reward center through CB1 receptors, independent of dopamine and opioid systems.
Comprehensive review documenting reliable THC self-administration in monkeys and major cannabinoid-opioid-dopamine interactions underlying reward and dependence.
Adolescent but not adult cannabinoid exposure in rats produced lasting cross-tolerance to morphine, cocaine, and amphetamine in dopamine reward neurons, suggesting unique adolescent brain vulnerability.
PET imaging study found heavy marijuana users (53-84 joints/week) still had brain activity changes and decision-making deficits after 25 days abstinent, while moderate users performed like non-users.
Activated CB1 receptors were routed to degradation via GASP1 in cells and neurons, offering a mechanistic link to receptor down-regulation.
A literature review described cannabis addiction as a chronic brain disease involving dopamine and serotonin pathways, with chronic use producing lasting effects on cognitive and reward brain circuits.
In a drug discrimination study, 8 participants reliably identified THC, but opioid, sedative, and stimulant drugs could not substitute for the THC experience.
Review of how endocannabinoid and opioid systems modulate nicotine addiction, suggesting new treatment targets.
fMRI study found chronic cannabis users had heightened brain reward responses to money and reduced sensitivity to losses compared to non-users.
Cannabinoid withdrawal physically shrank VTA dopamine neurons and reduced dendritic spines in the nucleus accumbens shell, supporting a "hypodopaminergic" addicted brain model.
Prenatal cannabis decreased D2 receptor expression in human fetal brain reward center; in rats, THC during pregnancy caused lasting epigenetic changes increasing offspring addiction vulnerability.
Review of how prenatal cannabis and cigarettes cause lasting brain changes: cannabis altered dopamine D2 receptors through epigenetic mechanisms, potentially programming lifelong addiction vulnerability.
Review of 23 studies found MDMA and cannabis co-use produced additive memory deficits, involving CB1-serotonin-dopamine interactions.
Brain imaging found adolescent methamphetamine and cannabis users had enlarged striatal regions and higher novelty-seeking, with meth exposure correlating to both.
Animal data place cannabis squarely in the dopamine reward circuit: dopamine rises with use and cues, and falls during withdrawal. Blocking endocannabinoid signaling blunts these effects.
CB1-expressing neurons in the brain's reward center are fast-spiking interneurons that become hyperexcitable during cocaine withdrawal, potentially suppressing reward circuit output.
Chronic cannabinoid treatment in monkeys caused up to 250-fold tolerance and cross-tolerance with methamphetamine and dopamine D2 drugs.
Rats showed increased CB1 receptor expression in a brain reward center throughout morphine withdrawal, and blocking these receptors reduced drug-seeking behavior.
A specific AKT1 gene variant determined whether THC impaired psychomotor control, with carriers showing increased errors and reduced brain activation in a motor control region.
In 14 regular users, lower dopamine synthesis in associative striatum tracked with higher apathy. No control group, and dose measures did not explain apathy.
In mice, orexin-1 signaling supported cannabinoid reward. Blocking it reduced self-administration and erased THC-evoked accumbens dopamine.
Mouse study found acute and repeated cocaine exposure produced distinct endocannabinoid and glutamate system changes in the cerebellum, implicating it in addiction processes.
Study of 463 adolescents found COMT gene methylation was linked to smoking, and a specific genotype-methylation interaction influenced high-frequency cannabis use.
Adolescent THC exposure affected heroin reward differently in addiction-prone vs. resilient rat strains, suggesting genetics determine whether cannabis acts as a gateway.
Mouse study discovered multiple interacting mechanisms controlling GABA release in the hippocampus, including constitutively active CB1 receptors and opposing endocannabinoid pathways.
Alcohol and cannabinoid signaling showed opposing effects at inhibitory synapses in the rat amygdala, with each system blocking the other's actions.
Brain imaging revealed that heavy cannabis users lacked the balanced dopamine receptor signaling between striatal regions that healthy controls displayed during a reaction-time task.
Adolescent THC exposure in rats produced over 1,000 regions of altered DNA methylation in their unexposed offspring's brain reward center, affecting glutamatergic signaling genes.
THC and a 2-AG boosting drug reduced brain reward self-stimulation in mice, while boosting anandamide alone had little effect, all mediated through CB1 receptors.
Novel synthetic cannabinoids AKB48 and 5F-AKB48 caused seizures, aggression, sensory impairment, and dopamine release in mice, with the fluorinated version being more potent.
Four third-generation Spice/K2 compounds showed CB1 binding up to 30x higher than JWH-018, with potent dopamine release in the brain's reward center.
Review of animal and human evidence shows chronic alcohol disrupts the endocannabinoid system, and CB1 receptor blockade reduces alcohol consumption and relapse, though psychiatric side effects remain a barrier to clinical use.
Animal study shows two synthetic cannabinoids found in "spice" products produce dangerous effects even at individually sub-threshold doses when combined, suggesting synergistic toxicity.
Controlled trial shows cannabis and cocaine increase impulsivity and reduce brain connectivity, but only in people with a genetic variant predisposing to higher dopamine levels.
Adolescent THC exposure in rats enhanced adult cannabinoid self-administration and blunted dopamine reward signaling, providing a biological mechanism for increased addiction vulnerability after early cannabis use.
Animal study found that both caffeine and cannabis altered neurotransmitter and enzyme levels in juvenile rat brains, with their combination producing amplified metabolic effects.
Mouse study found that boosting the endocannabinoid 2-AG through MAGL inhibition protected dopamine neurons in a Parkinson's model, while boosting anandamide through FAAH inhibition did not.
Lab study using human-derived neurons found high-dose THC (10 micromolar) disrupted neuronal function during dopaminergic development, while low doses had minimal effects.
Mouse study found CBD modestly reduced some THC behavioral effects but their combination produced unexpected epigenetic changes in the brain's reward pathway not seen with either compound alone.
PET imaging study found severely cannabis-dependent individuals had markedly reduced striatal dopamine release (effect size 1.48), correlating with cognitive deficits and negative symptoms.
Adolescent synthetic cannabinoid exposure triggered schizophrenia-like dopamine changes in genetically susceptible rats but not in non-susceptible rats, modeling the human gene-environment interaction.
A novel CB1 neutral antagonist reduced binge alcohol drinking and dopamine reward signaling in mice without the psychiatric side effects of previous CB1 blockers.
Brain imaging of 59 young men found early cannabis use altered hippocampal subregion volumes, with effects modified by the DAT1 dopamine transporter gene variant.
Crossover fMRI study found cannabis dampened the brain's reward response to music in the ventral striatum and other regions, but CBD restored normal connectivity and responses.
Mouse study found chronic THC rewired serotonin receptors toward a pro-psychotic signaling pattern via the Akt/mTOR pathway. Rapamycin blocked the effect.
Rhesus monkeys given daily THC for 12 weeks showed persistent working memory deficits (but not other cognitive domains) that recovered within 2 weeks of stopping. Dopamine D2/D3 receptors were unaffected.
fMRI study found cannabis use disorder participants showed altered prefrontal-striatal brain connectivity during working memory, with compensatory increases in some pathways offsetting decreases in others.
Randomized study found clozapine reduced cannabis craving and amygdala cue reactivity significantly more than risperidone in schizophrenia patients with cannabis use disorder.
Human Connectome Project analysis found cannabis-dependent individuals had hyperconnectivity in dopamine-related brain regions (striatum, midbrain), most pronounced in those who started youngest and reported high negative emotionality.
Boosting the brain's natural cannabinoid 2-AG enhanced fear memory in rats through CB2 receptors and mTOR suppression in the hippocampus - a previously unrecognized pathway.
A comprehensive review details how alcohol alters the endocannabinoid system to drive addiction, how CB1 receptors contribute to alcohol reward, and how ECS disruption contributes to fetal alcohol spectrum disorders.
A review distinguishes the endocannabinoid system's role in alcohol addiction (CB1 in reward circuits) from its role in fetal alcohol disorders (developmental ECS disruption), suggesting different therapeutic targets.
AKB48 stimulated dopamine reward pathways at low doses but caused hypothermia, catalepsy, and cardiac depression at higher doses, with all effects mediated through CB1 receptors.
A comprehensive neuroimaging review found cannabis affects executive, emotional, reward, and memory brain systems through direct and indirect pathways, with adolescent use carrying particular risk for lasting changes.
THC increased brain activity in attention and salience networks, with the COMT gene variant determining how executive networks responded, linking dopamine genetics to cannabis susceptibility.
A review found cannabinoid receptors modulate dopamine, serotonin, noradrenaline, GABA, glutamate, and opioid systems, explaining the broad spectrum of cannabis effects on mental health.
Rat study identifies ERK1-2 phosphorylation in the hippocampus as the molecular mechanism by which THC causes psychosis-like dopamine dysregulation and CBD reverses it.
Rat study shows adolescent cannabinoid exposure produces lasting reductions in prefrontal cortex activity during reward processing in adulthood, suggesting disrupted brain maturation.
Depression-model rats showed reduced endocannabinoid signaling with notable hemisphere-specific differences in prefrontal cortex and hippocampus.
Adolescent THC unexpectedly attenuated dopamine dysfunction caused by prenatal immune activation in rats, challenging the simple two-hit model of schizophrenia.
Alcohol conditioning decreased endocannabinoid levels in mouse brain reward regions, and CB2 receptor blockade reduced alcohol's rewarding effects.
Human neuroimaging study shows THC increases striatal glutamate and disrupts brain connectivity, with these changes predicting subjective high and attention deficits.
Overexpressing a cannabinoid receptor regulatory protein (CNRIP1) in rat brains produced schizophrenia-like behavioral and dopamine system changes.
COMT Val/Val carriers were most vulnerable to THC-induced cognitive deficits. A COMT inhibitor reduced these effects, but THC's psychosis-like effects were independent of dopamine.
A mouse model of a human FAAH gene variant showed that adolescent females had enhanced dopamine reward circuitry and stronger THC preference that lasted into adulthood, while males were unaffected.
The cannabinoid agonist HU-210 paradoxically reduced sucrose intake in rats by impairing licking motor mechanics via CB1 receptors, while rimonabant reduced intake through what may be reward devaluation.
A review found clear evidence that cannabis affects hippocampal function but weaker evidence for increased striatal dopamine, suggesting the cannabis-psychosis pathway may be more about hippocampal dysfunction than direct dopamine effects.
Rat study found CBD reduced cocaine self-administration and reward by attenuating dopamine release in the nucleus accumbens, working through CB2, serotonin 5-HT1A, and TRPV1 receptors.
Study comparing 201 cannabis-dependent patients to 285 controls found specific methylation differences at dopamine transporter gene sites bound by nervous system development transcription factors.
Review of 20 years of research found that alcohol produces its addictive brain effects and liver damage largely through the endocannabinoid system, particularly CB1 receptors.
Double-blind fMRI study found a single 600mg CBD dose did not alter reward-related brain activity or motivation in 23 healthy volunteers.
Study of 910 students found cannabis use predicted psychosis-like traits, with aberrant salience (abnormal importance assignment) mediating the relationship.
In a rat schizophrenia model, only the lowest THC dose (0.1 mg/kg) reversed social withdrawal, while higher doses worsened symptoms in healthy rats.
Heavy cannabis use was linked to lower BDNF levels in first-episode psychosis patients who had never taken antipsychotics, but not in healthy volunteers, suggesting vulnerability-specific effects.
THC caused dose-dependent repetitive behavior in zebrafish that was reduced by an antipsychotic and a CB2 receptor blocker but not a CB1 blocker, offering a new model for studying cannabis-psychosis links.
L-theanine pretreatment in adolescent rats prevented the long-term dopamine dysregulation, molecular changes, and behavioral abnormalities caused by THC exposure.
Rats exposed to THC around birth showed lasting epigenetic changes in dopamine receptor genes and schizophrenia-like behaviors, but adolescent CBD treatment reversed the damage. Similar epigenetic changes were found in human schizophrenia patients.
Review showing 2-AG endocannabinoids gate dopamine value signals across reward, timing, and threat avoidance — explaining why cannabis broadly affects motivation.
Review of how endocannabinoids and dopamine work as partners across Maslow's hierarchy — from survival drives to achievement — and how cannabis disrupts that partnership.
A CB1 receptor positive allosteric modulator called GAT211 showed antipsychotic-like effects in rats by reducing dopamine-related hyperactivity, unlike THC which did not block the same signaling pathway.
Cannabis activates the same dopamine reward pathway as all drugs of abuse. The endocannabinoid system's role in modulating these signals may offer new targets for treating addiction broadly.
Rat study finds prenatal THC creates a latent dopamine dysfunction in offspring that emerges as psychotic-like behavior only when triggered by stress or drug challenge.
Female rats showed biphasic THC anxiety responses that males didn't — anxiolytic at low doses, anxiogenic at high. CBD blocked the anxiety and enhanced the calm.
Animal study found THC's primary metabolite (11-OH-THC) was 7-31 times more potent than THC in mice, with female rats significantly more sensitive to THC than males.
A neutral CB1 antagonist reduced cocaine-seeking behavior and relapse in rodents through dopamine pathways without the side effects seen with rimonabant.
THC modulates reward-related brain regions in ways that correlate with psychotic symptoms. CBD appears to act in the opposite direction on the same regions.
Multimodal brain imaging of 24 heavy cannabis users found distinct structural and functional changes linked to serotonin, dopamine, and opioid receptor systems.
Schizophrenia patients with cannabis use disorder showed different blood biomarker patterns than those with schizophrenia alone, with elevated serotonin receptors and inflammation markers absent in dual-diagnosis patients.
THC withdrawal in mice disrupted dopamine release, sleep patterns, and behavior in ways that mirror human withdrawal, with more pronounced effects in males.
Researchers proposed a "cannabinoid hypothesis" of schizophrenia describing multiple biological pathways through which THC may trigger psychosis, paralleling established dopamine and serotonin hypotheses.
Review explained how the developing endocannabinoid system makes adolescent brains uniquely sensitive to THC, particularly through disruption of still-maturing dopamine circuits linked to psychosis and addiction.
Rat study found prenatal THC caused sex-specific brain lipid disruptions and neuropsychiatric-like behaviors in offspring, with males more persistently affected.
Largest fMRI study of cannabis and reward processing (125 participants) found no differences between users and non-users in reward anticipation, with adolescents showing no extra vulnerability.
Blocking the enzyme that degrades the brain's main endocannabinoid protected rat brain tissue through multiple receptor pathways.
Controlled fMRI study found THC blunted reward-related brain activity in adults but not adolescents. Adding CBD partially offset the effect in adults.
ABCD Study data linked prenatal cannabis exposure to blunted brain reward responses and psychotic-like experiences in youth, suggesting dopamine-related circuitry disruption.
Rat study found THC withdrawal reduced dopamine neuron firing in the brain's reward center, with functional changes in the habenula-RMTg circuit that may drive negative withdrawal states.
Chronic pain and addiction share a common neurobiological root — reduced dopamine signaling — explaining why pain patients who self-medicate with opioids or cannabis are vulnerable to escalating into misuse.
Prenatal THC exposure in rats amplified dopamine reward responses and opioid-seeking behavior, with male offspring showing greater vulnerability to relapse.
Boosting the endocannabinoid 2-AG in mice blocked opioid reward without reducing pain relief, suggesting a potential strategy to make opioid treatment less addictive.
Prenatal cannabis oil exposure altered VTA dopamine neurons in male mice (disinhibited firing) but did not increase cocaine-seeking in either sex.
Rat study found prenatal THC disrupted stress hormone receptors and dopamine signaling specifically in male offspring, causing stress vulnerability that was correctable with a developmental intervention.
Rodent brain study reveals stress hormone corticosterone triggers endocannabinoid (2-AG) production in a pain-control region, reducing inhibitory GABA signaling through CB1 receptors.
Mouse study finds CB1 receptors on dopamine neurons in the VTA-to-NAc circuit link trait anxiety to enhanced reward learning.
Rat study: CBD accelerated extinction of meth-seeking behavior and prevented relapse. Both effects required D1 dopamine receptors in the hippocampal dentate gyrus.
Prenatal THC exposure reprogrammed dopamine receptor expression in the prefrontal cortex of adolescent rats through epigenetic changes, with male offspring showing the strongest effects on D2 receptors, neuron excitability, and neural guidance systems.
A review of 15 studies found chronic substance use generally increases anandamide levels in the blood, suggesting the body's endocannabinoid system is disrupted across multiple types of addiction.
Cannabinoid receptor ligands reshaped energy metabolism in brain astrocytes, triggering calcium signaling, glycogen depletion, and increased metabolic output primarily through CB1 pathways.
Mice given THC during adolescence showed lasting social deficits, sensorimotor gating problems, and disrupted cortico-striatal brain connectivity with altered dopamine receptor balance persisting into adulthood.
An fMRI study found daily cannabis users had normal brain value signals for cannabis but disrupted signals for food rewards, supporting reward-narrowing theories of addiction.
CBD protected dopamine neurons and delayed motor symptoms in a progressive Parkinson mouse model, with preventive treatment working better than treatment started after symptom onset.
A review describes how new biosensor and imaging technologies are enabling researchers to track endocannabinoid signaling at individual synapses in living brains for the first time.
Prenatal THC increased anxiety in dominant mice offspring but decreased it in submissive ones, revealing that inborn temperament determines how prenatal cannabis exposure affects behavior.
Mouse study found amphetamine disrupted endocannabinoid-dependent brain plasticity through astrocyte CB1 receptors in males only, revealing a sex-specific mechanism in the reward system.
A study of 153 teens with mood symptoms found that cannabis users reported worse anticipatory anhedonia, with more frequent use linked to greater difficulty looking forward to pleasurable experiences.
CBD sped up extinction and prevented reinstatement of methamphetamine-seeking in rats, effects that were partially blocked by inhibiting D2 dopamine receptors in the hippocampus.
A review of 13 studies found emerging evidence that the endocannabinoid system may contribute to ADHD, with preclinical links between altered cannabinoid signaling and hyperactivity.
Mouse study found that combining a CB2 cannabinoid receptor activator with a dopamine D4 blocker reduced binge eating more effectively than the dopamine blocker alone.
PET imaging study of 29 people showing 13% lower dopamine D2 receptor availability in those testing positive for tobacco and/or cannabis smoke metabolites.
Rat study shows CBD helps extinguish meth-seeking behavior and prevents relapse through D2 dopamine receptors in the hippocampus, identifying a specific brain mechanism for CBD's anti-addiction potential.
Rat study shows prenatal THC exposure reduces adult motivation on effort-demanding tasks, especially in males, linked to attenuated dopamine responses in the brain's reward center.
Nature Neuroscience study reveals 2-AG and anandamide have completely separate cellular targets in the hippocampus, with 2-AG signaling to neurons and anandamide signaling to astrocytes.
First study showing alcohol decreases 2-AG endocannabinoid levels, with the drop linked to less drug liking, suggesting the endocannabinoid system mediates alcohol reward.
Study reveals endocannabinoids are stored alongside stress hormones in adrenal glands and directly modulate hormone production, connecting the ECS to the peripheral stress response.
Mouse study found low-dose THC increased dopamine and GABA in the brain's reward center while high doses decreased dopamine, and a partial CB1 agonist produced no reward-related effects.
THC produced consistent physiological effects in HIV-model rats without worsening motivation deficits, and chronic use showed tolerance to acute motivational impacts.